Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Biliary Cancer
Location:
Texas Oncology-Abilene
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Biliary Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Gateway
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Biliary Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Joe Battle
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Biliary Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Biliary Cancer
Location:
Texas Oncology-Midland Allison Cancer Center
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Biliary Cancer
Location:
Texas Oncology-Andrews
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Biliary Cancer
Location:
Texas Oncology-Odessa West Texas Cancer Center
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Biliary Cancer
Location:
Texas Oncology-Wichita Falls Cancer Center
Phase: III
Title:
Ph 3 Tuca/Placbo + T-DM1 HER2+ View
Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)
Indication:
Breast Cancer
Location:
Texas Oncology-Abilene
Phase: III
Title:
Ph 3 Tuca/Placbo + T-DM1 HER2+ View
Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)
Indication:
Breast Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Gateway
Phase: III
Title:
Ph 3 Tuca/Placbo + T-DM1 HER2+ View
Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)
Indication:
Breast Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
Ph 3 Tuca/Placbo + T-DM1 HER2+ View
Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)
Indication:
Breast Cancer
Location:
Texas Oncology-Midland Allison Cancer Center
Phase: III
Title:
Ph 3 Tuca/Placbo + T-DM1 HER2+ View
Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)
Indication:
Breast Cancer
Location:
Texas Oncology-Andrews
Phase: III
Title:
Ph 3 Tuca/Placbo + T-DM1 HER2+ View
Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)
Indication:
Breast Cancer
Location:
Texas Oncology-Odessa West Texas Cancer Center
Phase: III
Title:
Ph 3 Tuca/Placbo + T-DM1 HER2+ View
Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)
Indication:
Breast Cancer
Location:
Texas Oncology-Wichita Falls Cancer Center
Phase: III
Title:
STAR Ph3 Sinti vs Placebo ESCC View
Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301
Indication:
Esophageal Cancer
Location:
Texas Oncology-Abilene
Phase: III
Title:
STAR Ph3 Sinti vs Placebo ESCC View
Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301
Indication:
Esophageal Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Gateway
Phase: III
Title:
STAR Ph3 Sinti vs Placebo ESCC View
Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301
Indication:
Esophageal Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Joe Battle
Phase: III
Title:
STAR Ph3 Sinti vs Placebo ESCC View
Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301
Indication:
Esophageal Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR Ph3 Sinti vs Placebo ESCC View
Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301
Indication:
Esophageal Cancer
Location:
Texas Oncology-Midland Allison Cancer Center
Phase: III
Title:
STAR Ph3 Sinti vs Placebo ESCC View
Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301
Indication:
Esophageal Cancer
Location:
Texas Oncology-Andrews
Phase: III
Title:
STAR Ph3 Sinti vs Placebo ESCC View
Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301
Indication:
Esophageal Cancer
Location:
Texas Oncology-Odessa West Texas Cancer Center
Phase: III
Title:
STAR Ph3 Sinti vs Placebo ESCC View
Description: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301
Indication:
Esophageal Cancer
Location:
Texas Oncology-Wichita Falls Cancer Center
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Essential Thrombocythemia
Location:
Texas Oncology-Abilene
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Essential Thrombocythemia
Location:
Texas Oncology-El Paso Cancer Treatment Center Gateway
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Essential Thrombocythemia
Location:
Texas Oncology-El Paso Cancer Treatment Center Joe Battle
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Essential Thrombocythemia
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Essential Thrombocythemia
Location:
Texas Oncology-Midland Allison Cancer Center
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Essential Thrombocythemia
Location:
Texas Oncology-Andrews
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Essential Thrombocythemia
Location:
Texas Oncology-Odessa West Texas Cancer Center
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Essential Thrombocythemia
Location:
Texas Oncology-Wichita Falls Cancer Center
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-Abilene
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Gateway
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Joe Battle
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-Midland Allison Cancer Center
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-Andrews
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-Odessa West Texas Cancer Center
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-Wichita Falls Cancer Center
Phase: III
Title:
Ph3 GC4419 Oral Mucositis H&N View
Description: ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer (GTI-4419-301)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Gateway
Phase: III
Title:
Ph3 GC4419 Oral Mucositis H&N View
Description: ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer (GTI-4419-301)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Joe Battle
Phase: III
Title:
Ph3 GC4419 Oral Mucositis H&N View
Description: ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer (GTI-4419-301)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
Ph3 Adj canakinumab NSCLC View
Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)
Indication:
Lung Cancer
Location:
Texas Oncology-Abilene
Phase: III
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-Abilene
Phase: III
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Gateway
Phase: III
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Joe Battle
Phase: III
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-Midland Allison Cancer Center
Phase: III
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-Andrews
Phase: III
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-Odessa West Texas Cancer Center
Phase: III
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-Wichita Falls Cancer Center
Phase: III
Title:
STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View
Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
Indication:
Lung Cancer
Location:
Texas Oncology-Abilene
Phase: III
Title:
STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View
Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
Indication:
Lung Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Gateway
Phase: III
Title:
STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View
Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
Indication:
Lung Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Joe Battle
Phase: III
Title:
STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View
Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
Indication:
Lung Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View
Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
Indication:
Lung Cancer
Location:
Texas Oncology-Midland Allison Cancer Center
Phase: III
Title:
STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View
Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
Indication:
Lung Cancer
Location:
Texas Oncology-Andrews
Phase: III
Title:
STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View
Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
Indication:
Lung Cancer
Location:
Texas Oncology-Odessa West Texas Cancer Center
Phase: III
Title:
STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View
Description: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
Indication:
Lung Cancer
Location:
Texas Oncology-Wichita Falls Cancer Center
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Myelofibrosis
Location:
Texas Oncology-Abilene
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Myelofibrosis
Location:
Texas Oncology-El Paso Cancer Treatment Center Gateway
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Myelofibrosis
Location:
Texas Oncology-El Paso Cancer Treatment Center Joe Battle
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Myelofibrosis
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Myelofibrosis
Location:
Texas Oncology-Midland Allison Cancer Center
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Myelofibrosis
Location:
Texas Oncology-Andrews
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Myelofibrosis
Location:
Texas Oncology-Odessa West Texas Cancer Center
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)
Indication:
Myelofibrosis
Location:
Texas Oncology-Wichita Falls Cancer Center
Phase: III
Title:
PANOVA-3: 1L Gemcit + nab-pac pancreatic View
Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Gateway
Phase: III
Title:
PANOVA-3: 1L Gemcit + nab-pac pancreatic View
Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Joe Battle
Phase: III
Title:
PANOVA-3: 1L Gemcit + nab-pac pancreatic View
Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-Abilene
Phase: III
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Gateway
Phase: III
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Joe Battle
Phase: III
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-Midland Allison Cancer Center
Phase: III
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-Andrews
Phase: III
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-Odessa West Texas Cancer Center
Phase: III
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-Wichita Falls Cancer Center
Phase: III
Title:
STAR Ph3 Nirap+Abirat+Pred mCRPC View
Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Abilene
Phase: III
Title:
STAR Ph3 Nirap+Abirat+Pred mCRPC View
Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)
Indication:
Prostate Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Gateway
Phase: III
Title:
STAR Ph3 Nirap+Abirat+Pred mCRPC View
Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)
Indication:
Prostate Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Joe Battle
Phase: III
Title:
STAR Ph3 Nirap+Abirat+Pred mCRPC View
Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)
Indication:
Prostate Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR Ph3 Nirap+Abirat+Pred mCRPC View
Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Midland Allison Cancer Center
Phase: III
Title:
STAR Ph3 Nirap+Abirat+Pred mCRPC View
Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Andrews
Phase: III
Title:
STAR Ph3 Nirap+Abirat+Pred mCRPC View
Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Odessa West Texas Cancer Center
Phase: III
Title:
STAR Ph3 Nirap+Abirat+Pred mCRPC View
Description: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Wichita Falls Cancer Center
Phase: III
Title:
STAR Ph3 FGFR erdafitinib urothelial View
Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Abilene
Phase: III
Title:
STAR Ph3 FGFR erdafitinib urothelial View
Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Indication:
Urothelial Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Gateway
Phase: III
Title:
STAR Ph3 FGFR erdafitinib urothelial View
Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Indication:
Urothelial Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Joe Battle
Phase: III
Title:
STAR Ph3 FGFR erdafitinib urothelial View
Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Indication:
Urothelial Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR Ph3 FGFR erdafitinib urothelial View
Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Midland Allison Cancer Center
Phase: III
Title:
STAR Ph3 FGFR erdafitinib urothelial View
Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Andrews
Phase: III
Title:
STAR Ph3 FGFR erdafitinib urothelial View
Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Odessa West Texas Cancer Center
Phase: III